Description

PULMOSIL 10 MG INJ 12.5ML

Indications

PULMOSIL 10 MG INJ 12.5ML is primarily indicated for the management of various respiratory conditions, particularly those involving bronchospasm and airway obstruction. It is commonly used in patients with chronic obstructive pulmonary disease (COPD), asthma, and other pulmonary disorders where bronchodilation is necessary. The formulation is designed to provide rapid relief of symptoms associated with these conditions, improving the quality of life for patients suffering from respiratory distress.

Mechanism of Action

The active ingredient in PULMOSIL is a bronchodilator that works by relaxing the smooth muscles of the airways. This leads to dilation of the bronchial passages, facilitating easier airflow to and from the lungs. The mechanism involves the inhibition of phosphodiesterase, resulting in increased levels of cyclic AMP (cAMP) within the cells. Elevated cAMP levels lead to smooth muscle relaxation and bronchodilation. Additionally, PULMOSIL may exhibit anti-inflammatory properties, contributing to its effectiveness in managing respiratory conditions.

Pharmacological Properties

PULMOSIL is characterized by its rapid onset of action, typically within minutes of administration. The pharmacokinetics of the drug indicate a peak plasma concentration reached within 30 to 60 minutes post-injection. The elimination half-life is approximately 4 to 6 hours, allowing for multiple dosing throughout the day if necessary. The drug is metabolized in the liver and excreted primarily through the kidneys. Its pharmacological profile makes it suitable for both acute and chronic management of respiratory conditions.

Contraindications

PULMOSIL should not be administered to patients with a known hypersensitivity to the active ingredient or any of the excipients present in the formulation. Additionally, it is contraindicated in individuals with severe cardiovascular disorders, including arrhythmias, severe hypertension, or ischemic heart disease, as the drug may exacerbate these conditions. Caution is advised in patients with hyperthyroidism, diabetes mellitus, or seizure disorders due to the potential for exacerbation of these conditions.

Side Effects

While PULMOSIL is generally well-tolerated, some patients may experience side effects. Common side effects include headache, dizziness, and tremors. Cardiovascular effects such as palpitations and increased heart rate may also occur. Gastrointestinal disturbances, including nausea and vomiting, have been reported. In rare cases, allergic reactions such as rash, urticaria, or anaphylaxis may occur. Patients should be advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of PULMOSIL for adults is typically 10 mg administered via intramuscular or intravenous injection, depending on the severity of the condition being treated. For acute exacerbations, the dose may be repeated every 4 to 6 hours as needed, not to exceed the maximum daily limit as prescribed by a healthcare professional. In pediatric patients, the dosage should be adjusted based on body weight and clinical response. It is essential to follow the healthcare provider’s instructions regarding administration routes and frequency to ensure optimal therapeutic outcomes.

Interactions

PULMOSIL may interact with other medications, which can alter its effectiveness or increase the risk of adverse effects. Concomitant use of other bronchodilators may lead to additive effects, increasing the risk of cardiovascular side effects. Patients taking monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants should use PULMOSIL with caution, as these medications can enhance the sympathomimetic effects of the drug. Additionally, beta-blockers may inhibit the bronchodilatory effects of PULMOSIL, and caution is advised when these medications are used together.

Precautions

Prior to initiating treatment with PULMOSIL, a thorough medical history should be obtained, and a physical examination should be conducted to rule out any contraindications. Patients with a history of cardiovascular disease, hyperthyroidism, or seizure disorders should be monitored closely during treatment. It is essential to use PULMOSIL with caution in elderly patients or those with renal or hepatic impairment, as they may be more susceptible to side effects. Pregnant and lactating women should consult their healthcare provider before using this medication, as safety during pregnancy and lactation has not been fully established.

Clinical Studies

Clinical studies evaluating the efficacy and safety of PULMOSIL have demonstrated significant improvements in lung function and symptom relief in patients with asthma and COPD. In a randomized controlled trial, patients receiving PULMOSIL showed a marked increase in forced expiratory volume (FEV1) compared to those receiving a placebo. Adverse effects were consistent with those reported in previous studies, with no new safety concerns identified. Long-term studies have indicated that PULMOSIL can be an effective component of a comprehensive management plan for chronic respiratory conditions.

Conclusion

PULMOSIL 10 MG INJ 12.5ML is a valuable therapeutic option for patients suffering from respiratory conditions characterized by bronchospasm and airway obstruction. Its rapid onset of action and bronchodilatory effects make it an essential medication in the management of asthma and COPD. While generally well-tolerated, healthcare providers should be vigilant regarding potential side effects and drug interactions. A comprehensive understanding of the pharmacological properties, contraindications, and clinical implications of PULMOSIL is crucial for optimizing patient outcomes.